Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate-day vs daily house dust mite sublingual immunotherapy in allergic rhinitis
TCTR20250107010Phase 2Recruiting
- Sponsor
- Abbott Laboratories
- Start
- Mar 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of standardized house dust mite extract in allergic rhinitis (AR), sponsored by Abbott Laboratories. Started Mar 2025; status: recruiting.
02
Drugs
standardized house dust mite extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on TCTR20250107010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250107010.